Umer Raffat
Stock Analyst at Evercore ISI Group
(1.31)
# 3,343
Out of 4,670 analysts
21
Total ratings
50%
Success rate
-9.36%
Average return
Main Sectors:
Stocks Rated by Umer Raffat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Initiates: Outperform | n/a | $27.70 | - | 1 | Jul 16, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: In-Line | n/a | $5.27 | - | 2 | Mar 8, 2024 | |
| GUTS Fractyl Health | Initiates: Outperform | n/a | $2.09 | - | 1 | Feb 28, 2024 | |
| RAPT RAPT Therapeutics | Initiates: Outperform | n/a | $1.08 | - | 1 | Feb 16, 2024 | |
| ALKS Alkermes | Upgrades: Outperform | n/a | $28.78 | - | 1 | Oct 24, 2023 | |
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | n/a | $17.04 | - | 1 | Jun 21, 2023 | |
| TEVA Teva Pharmaceutical | Upgrades: Outperform | n/a | $17.12 | - | 1 | May 18, 2023 | |
| PHAT Phathom Pharmaceuticals | Upgrades: Outperform | n/a | $9.34 | - | 3 | May 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Outperform | n/a | $12.49 | - | 1 | Mar 7, 2023 | |
| LEGN Legend Biotech | Initiates: Outperform | n/a | $40.94 | - | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.28 | - | 1 | Jun 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.19 | - | 1 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $0.79 | +5,975.95% | 1 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $294.53 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,040 | $16.77 | +6,099.81% | 1 | Mar 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $5.37 | +793.85% | 1 | Jun 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $126.67 | - | 1 | Feb 23, 2017 |
Spyre Therapeutics
Jul 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $27.70
Upside: -
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $5.27
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $2.09
Upside: -
RAPT Therapeutics
Feb 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.08
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $28.78
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $17.04
Upside: -
Teva Pharmaceutical
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $17.12
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $9.34
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $12.49
Upside: -
Legend Biotech
Nov 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $40.94
Upside: -
Jun 10, 2021
Initiates: Outperform
Price Target: n/a
Current: $15.28
Upside: -
Mar 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.19
Upside: -
Mar 3, 2021
Initiates: Outperform
Price Target: $48
Current: $0.79
Upside: +5,975.95%
Jan 21, 2020
Upgrades: Outperform
Price Target: n/a
Current: $294.53
Upside: -
Mar 19, 2018
Initiates: Outperform
Price Target: $1,040
Current: $16.77
Upside: +6,099.81%
Jun 30, 2017
Initiates: Outperform
Price Target: $48
Current: $5.37
Upside: +793.85%
Feb 23, 2017
Initiates: Buy
Price Target: n/a
Current: $126.67
Upside: -